Pegloticase therapy is associated with which route of administration?

• A. Intravenous infusion
• B. Oral tablet
• C. Subcutaneous injection
• D. Intramuscular injection

Answer: (A)

Palg... No, the main idea to remember is that this therapy is a protein-based biologic, so it must be given by intravenous infusion. Pegloticase is a pegylated recombinant uricase enzyme. As a protein, it would be digested and inactivated if taken by mouth, so oral administration would not produce therapeutic levels. Subcutaneous or intramuscular routes aren’t used because the pharmacokinetics and exposure needed for predictable uric acid lowering are best achieved with IV delivery, and IV administration allows monitoring for potential infusion-related reactions. In clinical practice, it’s given as an intravenous infusion (often over about 2 hours) every two weeks, with premedication to reduce hypersensitivity risks.